Century Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CENTURY THERAPEUTICS, INC. | |
| By: | /s/ Brent Pfeiffenberger, PharmD, MBA |
| Brent Pfeiffenberger, PharmD, MBA | |
| Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | | Title | | Date |
|---|---|---|---|---|
| /s/ Brent Pfeiffenberger, PharmD, MBA | Chief Executive Officer and Chairman of the Board (principal executive officer) | March 12, 2026 | ||
| Brent Pfeiffenberger, PharmD, MBA | ||||
| | | | ||
| /s/ Douglas Carr, CPA | | Senior Vice President, Finance & Operations | | March 12, 2026 |
| Douglas Carr, CPA | | (principal financial and accounting officer) | | |
| | | | | |
| /s/ Kimberly Blackwell, M.D. | Director | March 12, 2026 | ||
| Kimberly Blackwell, M.D. | ||||
| | | | | |
| /s/ Han Lee, Ph.D | Director | March 12, 2026 | ||
| Han Lee, Ph.D | ||||
| | | | | |
| /s/ Martin Murphy, Ph.D. | Director | March 12, 2026 | ||
| Martin Murphy, Ph.D. | ||||
| | | | | |
| /s/ Alessandro Riva, M.D. | Director | March 12, 2026 | ||
| Alessandro Riva, M.D. | ||||
| | | | | |
| /s/ Timothy Walbert | | Director | | March 12, 2026 |
| Timothy Walbert | | | ||
| | | | | |
| /s/ Daphne Quimi | | Director | | March 12, 2026 |
| Daphne Quimi | | | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.